OKYO Pharma Ltd., an ophthalmology-focused biopharmaceutical company, has announced the receipt of $1.9 million in non-dilutive funding to advance the clinical development of urcosimod, its lead drug candidate for the treatment of Neuropathic Corneal Pain (NCP). This funding will be used to support ongoing research and development activities, specifically targeting the acceleration of urcosimod's clinical milestones and regulatory pathway. As of now, there are no FDA-approved therapies for NCP, a condition known for its chronic and severe nerve-related pain. The infusion of capital allows OKYO Pharma to continue its development strategy without affecting existing shareholder equity. No specific results from clinical studies or trials have been presented at this time.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.